Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine

NCT ID: NCT05718037

Last Updated: 2023-02-08

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-01
• Study Completion Date: 2024-07-31

Brief Summary

This is a phase I, randomized, observer-blinded study to evaluate the safety, tolerability, and immunogenicity of BV211(a herpes zoster vaccine) in Adult Volunteers.

Conditions

Herpes Zoster

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

LY

Young adult subjects received low dose of BV211

Group Type: EXPERIMENTAL

Recombinant Zoster Vaccine

Intervention Type: BIOLOGICAL

0.5mL, Intramuscular

HY

Young adult subjects received high dose of BV211

Group Type: EXPERIMENTAL

Recombinant Zoster Vaccine

Intervention Type: BIOLOGICAL

0.5mL, Intramuscular

Placebo

Young adult subjects received placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: BIOLOGICAL

0.5mL, Intramuscular

LO

Old adult subjects received low dose of BV211

Group Type: EXPERIMENTAL

Recombinant Zoster Vaccine

Intervention Type: BIOLOGICAL

0.5mL, Intramuscular

HO

Old adult subjects received high dose of BV211

Group Type: EXPERIMENTAL

Recombinant Zoster Vaccine

Intervention Type: BIOLOGICAL

0.5mL, Intramuscular

Control Vaccine

Old adult subjects received control vaccine

Group Type: ACTIVE_COMPARATOR

Zoster Vaccine Recombinant, Adjuvanted

Intervention Type: BIOLOGICAL

0.5mL, Intramuscular

Interventions

Recombinant Zoster Vaccine

0.5mL, Intramuscular

Intervention Type: BIOLOGICAL

Placebo

0.5mL, Intramuscular

Intervention Type: BIOLOGICAL

Zoster Vaccine Recombinant, Adjuvanted

0.5mL, Intramuscular

Intervention Type: BIOLOGICAL

Other Intervention Names

BV211; Shingrix

Eligibility Criteria

Inclusion Criteria

• Healthy resident aged 30-70 years with body weight ≥ 50 kg for males and ≥ 45 kg for females, BMI within the range of 19.0-32.0 (including the boundary value), who can provide legal identification.
• Willing to participate in the study and sign ICF.
• Women of childbearing age shall take effective contraception measures 30 days before vaccination up to 6 months post full vaccination and not in lactation period. The pregnancy test on the day of vaccination shall be negative.
• Will attend all scheduled follow-up visits and follow the requirements of the clinical study.

Exclusion Criteria

• Smoking, and/or excessive alcohol use.
• Failed the screening test of illicit drugs, including THC.
• Axillary temperature above 37.3℃.
• History of herpes zoster.
• Received any herpes zoster vaccine.
• Received any vaccine within 14 days or live vaccine within 28 days before vaccination.
• Received gamma immunoglobulin or intravenous immunoglobulin within 3 months before vaccination.
• Have acute illness or are in the acute exacerbation phase of a chronic disease within 3 days before vaccination.
• Allergic history to any vaccine-related component; history of severe allergies to any vaccine.
• History of convulsions, epilepsy or encephalopathy (such as congenital brain hypoplasia, brain trauma, brain tumor, cerebral hemorrhage, cerebral infarction, brain infection, damage to nerve tissue in brain caused by chemical drug poisoning, etc.) and psychiatric history or family history of mental illness.
• Asplenia or functional asplenia, and asplenia or splenectomy caused by any reason.
• Primary or secondary immunocompromised or diagnosed with congenital or acquired immunodeficiency, infection of HIV, lymphoma, leukemia, SLE, JRA, inflammatory bowel disease or other autoimmune diseases.
• Received immunosuppressive therapy (such as long-term application of systemic glucocorticoids ≥ 14 days, dose ≥ 2 mg/kg/day or prednisone ≥ 20mg/day or equivalent to that dose of prednisone, excluding inhaled, intra-articular and topical steroid) within 3 months before vaccination.
• Serious cardiovascular diseases (pulmonary heart disease, pulmonary edema), liver and renal diseases and diabetes with complications.
• History of thrombocytopenia or other coagulation disorders, which may cause contraindications to intramuscular injection.
• Abnormal blood pressure (systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg) before vaccination; abnormal ECG
• Laboratory indicators out of the specified ranges (i.e., out of 1.5x of ULN or LLN), or with clinical significance as judged by the physician.
• Current/long-term history of alcohol abuse and/or history of drug abuse.
• Any other factors judged by investigator that may affect the safety of the subject or evaluation of the study.

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Shanghai BravoBio Co., Ltd.

UNKNOWN

Sponsor Role: collaborator

Wuhan BravoVax Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

BV-C211-202301

Identifier Type: -

Identifier Source: org_study_id